Balyasny Asset Management LLC Takes $607000 Position in ABIOMED, Inc. (ABMD)

CIBH's SI was 1,100 shares in October as released by FINRA. With 5,100 avg volume, 0 days are for CIB MARINE BANCSHS (OTCMKTS:CIBH)'s short sellers to cover CIBH's short positions. 208,953 shares of the stock traded hands.

The stock decreased 0.18% or GBX 0.12 on October 26, reaching GBX 68. It has underperformed by 16.70% the S&P500. Abiomed Inc now has $7.91 billion valuation.

Abiomed shares have risen 52 percent since the beginning of the year. The latest exchange of 1.15 Million shares is below its average trading activity of 312.23 Million shares. (NASDAQ:ABMD) to report earnings on Oct, 26 for the fiscal quarter ending Sep 2017. It has outperformed by 24.43% the S&P500.

Investors sentiment increased to 1.43 in 2017 Q2. ABMD is covered by 10 analysts who, by consensus, are bullish with earnings estimated to increase from current levels of $1.76 to $3.87 over the next couple of years. It is positive, as 21 investors sold ABMD shares while 86 reduced holdings. BNP Paribas Arbitrage SA raised its position in ABIOMED by 45.3% during the 2nd quarter. Nebraska-based Ameritas Inv Inc has invested 0.08% in ABIOMED, Inc.

ABMD has been the subject of several recent research reports. Signaturefd Ltd Com owns 4,365 shares. Balasa Dinverno & Foltz Ltd Liability invested in 0.06% or 2,611 shares.


If we look at the Volatility of ABIOMED, Inc. Artemis Investment Management Ltd Liability Partnership stated it has 0.11% in ABIOMED, Inc. Sheets Smith Wealth Management holds 2,249 shares. 419.99 million shares or 3.18% less from 433.79 million shares in 2017Q1 were reported. Guggenheim Cap Lc holds 0.06% or 167,867 shares in its portfolio. (NASDAQ:ABMD). 1St Advisors owns 4,971 shares or 0.08% of their USA portfolio. (NASDAQ:ABMD). Paloma Prns Mgmt Com reported 10,500 shares or 0.02% of all its holdings.

ABIOMED, Inc.'s insider ownership stands at 1.7 percent, while its insider transaction is -12.37 percent. It also upped Acceleron Pharma (NASDAQ:XLRN) stake by 478,099 shares and now owns 604,499 shares. The stock of ABIOMED, Inc. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 37 cents per share. Therefore 83% are positive. ABIOMED, Inc. has a 12-month low of $95.14 and a 12-month high of $183.96. This means ABMD has already proven its capacity to grow at a strong rate, which should give investors higher conviction of analysts' consensus prediction for the company's future growth going forward. Abiomed had 23 analyst reports since August 4, 2015 according to SRatingsIntel. Leerink Swann maintained it with "Outperform" rating and $125 target in Wednesday, May 4 report. The firm has "Buy" rating given on Tuesday, August 18 by Sterne Agee CRT. The firm has "Hold" rating given on Wednesday, August 5 by Piper Jaffray. The firm has "Hold" rating by BTIG Research given on Tuesday, August 4. Leerink Swann maintained ABIOMED, Inc. (NASDAQ:ABMD) earned "Outperform" rating by Raymond James on Friday, October 30. SunTrust Banks, Inc. started coverage on shares of ABIOMED in a report on Friday, September 29th. The firm has "Buy" rating by Jefferies given on Thursday, August 3. RBC Capital Markets maintained Boeing Co (NYSE:BA) on Thursday, October 22 with "Sector Perform" rating. Corporate insiders own 7.00% of the company's stock. In the last quarter, insiders sold 61,782 shares of company stock worth $9,513,610. Weber David M sold 21,250 shares worth $2.78M. About 890,673 shares traded or 198.20% up from the average.

ABIOMED, Inc.is a provider of temporary percutaneous mechanical circulatory support devices. ABIOMED, Inc. The stock has a market capitalization of $8.01 billion, a price-to-earnings ratio of 106.18 and a beta of 0.27. The Company offers care to heart failure patients. It has a 104.22 P/E ratio. The Firm operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart.

CIB Marine Bancshares, Inc.is a financial services holding company. The company has 43.49 Million shares outstanding and 42.99 Million shares were floated in market. It has a 13.18 P/E ratio.

Receive ABIOMED, Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED, Inc. with MarketBeat.com's FREE daily email newsletter.

Related:

Comments

Latest news

Schlumberger Limited (NYSE:SLB)
Equities research analysts forecast that Schlumberger NV will post $1.12 EPS for the current year. (NYSE:SLB). Schlumberger Ltd now has $85.72B valuation. (SLB) traded up 0.371% during trading on Monday, hitting $63.605.

Donald Trump Just Told a Trick-or-Treating Child
Res recalled Trump telling her. "Well, congratulations, folks", the president told journalists on Friday, wrapping up the photo op .

Reliance Nippon AMC public offer oversubscribed 81.5 times
As of 12pm, the IPO received bids for 428,916,489 shares against the total issue size of 42,840,000 shares, according to NSE data. The portions reserved for institutional investors and high net worth individuals have been subscribed more than 100 times each.

Kathy Griffin Rips 'Deeply Misogynistic' Andy Cohen
Cooper, pressured at the time to take a stand on the photo, tweeted that it was "clearly disgusting and completely inappropriate". Kathy Griffin is furious at her former Bravo executive Andy Cohen for some comments he made to a TMZ reporter recently.

Bowling Portfolio Management LLC Lowers Stake in Johnson & Johnson (JNJ)
The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.80 by $0.10. On average, equities analysts predict that Johnson & Johnson will post $7.28 earnings per share for the current fiscal year.

Other news